

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Shanghai HeartCare Medical Technology Corporation Limited**

**上海心璋醫療科技股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6609)**

### **ANNOUNCEMENT ON THE PROGRESS OF LITIGATION**

This announcement is made by Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”), together with its subsidiaries, the “**Group**”) on a voluntary basis.

Reference is made to the annual report of the Company for the year ended December 31, 2021, the interim report of the Company for the six months ended June 30, 2021 and the prospectus of the Company dated August 10, 2021 (the “**Prospectus**”), in which it was disclosed that in April 2021, the Company was notified by the Intermediate Court of Ningbo City, Zhejiang Province (the “**Court**”) about certain intellectual property (“**IP**”) infringement claims (the “**IP Infringement Claims**”) brought against the Company by Medtronic, Inc. (“**Medtronic**”), a medical technology company incorporated in the United States. Medtronic alleges that our Company, by manufacturing and selling the Captor™ thrombectomy device in China, infringed two Chinese inventions patents held by Medtronic. Please refer to the Prospectus for more details on the IP Infringement Claims.

The board of directors of the Company (the “**Board**”) is pleased to announce that the Court has handed down its rulings on May 31, 2022. The Court is notified that the China National Intellectual Property Administration (國家知識產權局) had invalidated the two patents relied on by the IP Infringement Claims. For this reason, the Court has dismissed the IP Infringement Claims. Further announcement(s) will be made by the Company if there are any further material updates to the IP Infringement Claims.

**Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.**

By order of the Board  
**Shanghai HeartCare Medical Technology Corporation Limited**  
**Wang Guohui**  
*Chairman of the Board*

Shanghai, May 31, 2022

*As at the date of this announcement, the executive Directors are Mr. Wang Guohui and Ms. Zhang Kun; the non-executive Directors are Mr. Ding Kui, Mr. Chen Gang and Mr. Ouyang Xiangyu; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.*